- Home
- BEN vs PCVX Comparison
BEN vs PCVX Comparison
Compare BEN & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEN
- PCVX
- Stock Information
- Founded
- BEN 1947
- PCVX 2013
- Country
- BEN United States
- PCVX United States
- Employees
- BEN N/A
- PCVX N/A
- Industry
- BEN Investment Managers
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- BEN Finance
- PCVX Health Care
- Exchange
- BEN Nasdaq
- PCVX Nasdaq
- Market Cap
- BEN 10.5B
- PCVX 9.6B
- IPO Year
- BEN N/A
- PCVX 2020
- Fundamental
- Price
- BEN $19.28
- PCVX $69.46
- Analyst Decision
- BEN Sell
- PCVX Strong Buy
- Analyst Count
- BEN 11
- PCVX 9
- Target Price
- BEN $20.80
- PCVX $147.50
- AVG Volume (30 Days)
- BEN 3.9M
- PCVX 1.1M
- Earning Date
- BEN 04-28-2025
- PCVX 05-07-2025
- Dividend Yield
- BEN 6.64%
- PCVX N/A
- EPS Growth
- BEN N/A
- PCVX N/A
- EPS
- BEN 0.66
- PCVX N/A
- Revenue
- BEN $8,738,500,000.00
- PCVX N/A
- Revenue This Year
- BEN N/A
- PCVX N/A
- Revenue Next Year
- BEN N/A
- PCVX N/A
- P/E Ratio
- BEN $29.43
- PCVX N/A
- Revenue Growth
- BEN 10.99
- PCVX N/A
- 52 Week Low
- BEN $18.83
- PCVX $58.10
- 52 Week High
- BEN $28.08
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- BEN 40.04
- PCVX 37.80
- Support Level
- BEN $19.62
- PCVX $68.36
- Resistance Level
- BEN $20.21
- PCVX $76.61
- Average True Range (ATR)
- BEN 0.46
- PCVX 3.10
- MACD
- BEN -0.00
- PCVX 0.01
- Stochastic Oscillator
- BEN 28.20
- PCVX 23.81
About BEN Franklin Resources Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of April 2024, Franklin had $1.602 trillion in managed assets, composed primarily of equity (35%), fixed-income (35%), multi-asset/balanced (10%) funds, alternatives (16%) and money market funds (4%). Distribution tends to be weighted equally between retail investors (52% of AUM) and institutional accounts (46%), with high-net-worth clients accounting for the remainder. Franklin is one of the more global of the US-based asset managers we cover, with more than a third of its assets under management invested in global/international strategies and 30% of managed assets sourced from clients domiciled outside the United States.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.